Horizon Discovery Group PLC (LON:HZD)‘s stock had its “speculative buy” rating restated by equities researchers at Beaufort Securities in a note issued to investors on Thursday.

A number of other research analysts have also recently commented on the stock. Numis Securities Ltd restated a “buy” rating and issued a GBX 260 ($3.25) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, November 16th. Panmure Gordon restated a “buy” rating and issued a GBX 205 ($2.56) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, November 9th. Finally, N+1 Singer restated a “buy” rating and issued a GBX 194 ($2.42) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, November 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of GBX 217.25 ($2.71).

Analyst Recommendations for Horizon Discovery Group PLC (LON:HZD)

Shares of Horizon Discovery Group PLC (LON:HZD) opened at 124.00 on Thursday. The stock has a 50 day moving average of GBX 134.58 and a 200-day moving average of GBX 153.39. The company’s market capitalization is GBX 116.71 million. Horizon Discovery Group PLC has a 52 week low of GBX 123.00 and a 52 week high of GBX 188.06.

About Horizon Discovery Group PLC

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Stock Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related stocks with our FREE daily email newsletter.